OK on Arthritis Test Lifts Hycor Stock 35%
(Dow Jones)
Hycor Biomedical Inc.’s stock climbed to a 52-week high Tuesday after the company said it received regulatory approval to market in the U.S. an autoimmune test for rheumatoid arthritis.
The stock, which has gained 400% this year, hit $8.88 before closing at $8.75, up $2.75, or nearly 35%.
Hycor, a Garden Grove maker of diagnostic products, said the test, which was approved by the Food and Drug Administration, can be performed manually or through an automated system.
